Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Provectus BiopharmaceuticalsSTU:PXY 35 Piotroski F-Score is 2 as of Aug. 03, 2026, which is at its 10-year median of 2.00. GuruFocus rates STU:PXY with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,331 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 73.1% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Provectus Biopharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Provectus Biopharmaceuticals's Piotroski F-Score or its related term are showing as below:
STU:PXY'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 2 Max: 4
Current: 2
During the past 13 years, the highest Piotroski F-Score of Provectus Biopharmaceuticals was 4. The lowest was 1. And the median was 2.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Provectus Biopharmaceuticals Piotroski F-Score Related Terms
Provectus Biopharmaceuticals Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PXY vs PSTV, ALGS, ATNM: Piotroski F-Score Comparison
For the Biotechnology subindustry, Provectus Biopharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provectus Biopharmaceuticals Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Provectus Biopharmaceuticals's current Net Income (TTM) was -4.90.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Provectus Biopharmaceuticals's current Cash Flow from Operations (TTM) was -2.22.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Provectus Biopharmaceuticals's return on assets of this year was -7.94967532. Provectus Biopharmaceuticals's return on assets of last year was -5.0795569.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Provectus Biopharmaceuticals's gearing of this year was 0.10756677. Provectus Biopharmaceuticals's gearing of last year was 0.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Provectus Biopharmaceuticals's current ratio of this year was 0.06353768. Provectus Biopharmaceuticals's current ratio of last year was 0.11310085.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Provectus Biopharmaceuticals's number of shares in issue this year was 420.28. Provectus Biopharmaceuticals's number of shares in issue last year was 420.28.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Provectus Biopharmaceuticals's gross margin of this year was . Provectus Biopharmaceuticals's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Provectus Biopharmaceuticals's asset turnover of this year was 0. Provectus Biopharmaceuticals's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
1
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Provectus Biopharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Provectus Biopharmaceuticals (STU:PXY) has a Piotroski F-Score of 2 as of Aug. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Provectus Biopharmaceuticals and its competitors. This is near median its historical median of 2.00. Over the past decade, Provectus Biopharmaceuticals' Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #973 out of 1331 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Provectus Biopharmaceuticals' Piotroski F-Score too high?
Provectus Biopharmaceuticals' current Piotroski F-Score of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Provectus Biopharmaceuticals' value of 2 is 33.3% below this industry median. Based on the distribution chart, Provectus Biopharmaceuticals ranks #973 out of 1331 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Provectus Biopharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Provectus Biopharmaceuticals' Piotroski F-Score compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #973 out of 1331 companies for Piotroski F-Score. This places Provectus Biopharmaceuticals in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Provectus Biopharmaceuticals' value of 2 is 33.3% below this benchmark. Historically, Provectus Biopharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 3.00, Provectus Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Provectus Biopharmaceuticals's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Provectus Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provectus Biopharmaceuticals's current Piotroski F-Score is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (STU:PXY) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is near median its 10-year median of 2.00 and 33.3% below the Biotechnology industry median of 3.00. Provectus Biopharmaceuticals' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Provectus Biopharmaceuticals (STU:PXY), the current Piotroski F-Score is 2 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score
Get the complete analysis for STU:PXY
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PXY has been successfully added to your 
